<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Biochemistry</strong>/<strong>Molecular</strong> <strong>Biology</strong>2011-289033 “DYNANO” and BM1202 European Network onMicrovesicles and Exosomes in Health and Disease (ME-HAD).Bence György is a Kerpel-Fronius Ödön Fellows.Program Number: 3149Presentation Time: 11:15 AM - 11:30 AMNephrocystin-5 knockout mice recapitulate retina and kidneypathologies of Senior-Løken SyndromeCecinio Ronquillo, Jeanne M. Frederick, Wolfgang Baehr.Ophthalmology and Visual Sciences, Moran Eye Center, Universityof Utah, Salt Lake City, UT.Purpose: Senior-Løken syndrome is an autosomal recessive diseasecharacterized by retinal degeneration (RP/LCA) andnephronophthisis (kidney fibrosis and presence of cysts). Mutationsin Nephrocystin-5 (NPHP5) have been shown to be the most commoncause of Senior-Løken syndrome in humans; however, the function ofNPHP5 is poorly understood. Here, we describe a novel mammalianmodel of Senior-Løken syndrome generated by deleting NPHP5 inthe mouse.Methods: A gene trap containing a reporter gene (β-gal) was insertedin intron 4 of the mouse Nphp5 gene causing premature terminationof Nephrocystin-5 protein expression. Retina and renal tissue werecharacterized by immunocystochemistry using various antibodies atdevelopmental time points. ERGs were recorded at different timepoints. Ultrastructure of the photoreceptor connecting cilium andbasal body was examined on postnatal days P6 and P10.Results: Global knockout mice are viable and fertile. Retinalfunction in knockout animals was undetectable by ERG at P12 (eyeopening). At P10, knockout animals already showed absence of outersegments and decreased number of cells in the outer nuclear layer.Rhodopsin transport is impaired as early as P6 and rhodopsinaccumulates in rod perinuclear regions (Fig. 1). Apoptosis, fibrosisand presence of cysts are observed in the kidneys of knockout mice(Fig. 2). Knockdown of NPHP5 in a kidney cell line shows decreasednumbers of primary cilia suggesting a role of NPHP5 in ciliogenesisor ciliary maintenance.Conclusions: NPHP5 global knockout mouse is a novel model ofSenior-Løken syndrome recapitulating the retina and renalpathologies observed in humans. This model will be an importanttool to provide insight into detailed molecular mechanisms of NPHP5function in ciliogenesis and primary cilium structure.Figure 1. Rhodopsin mislocalizes to rod perinuclear regions of P10NPHP5 KO retina (red arrow). Rhodopsin (green, 1D4), cone arrestin(red, mCAR), nuclei (blue, DAPI).Figure 2. NPHP5 knockout kidneys have increased cell death byTUNEL stain (green). Also shown is an example of a cyst present inknockout kidneys (red arrow).Commercial Relationships: Cecinio Ronquillo, None; Jeanne M.Frederick, None; Wolfgang Baehr, NoneSupport: National Eye Institute F31 NRSA - F31EY021972-01A1Program Number: 3150Presentation Time: 11:30 AM - 11:45 AMLong-term preservation of immature cone-like photoreceptors ina mouse model of human LCA caused by dominant CRXframeshift mutationJerome E. Roger 1 , Avinash H. Hiriyanna 1 , Debbie F. Cheng 1 ,Norimoto Gotoh 1 , Rinki Ratna Priya 1 , Matthew Brooks 1 , Harsha K.Rajasimha 1 , Bo Chang 2 , Anand Swaroop 1 . 1 Neurobiol-Neurodegnt'nRep Lab, NEI / National Institutes of Health, Bethesda, MD; 2 TheJackson Laboratory, Bar Harbor, ME.Purpose: Leber’s congenital amaurosis (LCA) is a severe form ofchildhood blindness representing 5% of all retinopathies. Mutationsin CRX, a key transcription factor for photoreceptor development, areassociated with retinal dystrophies including LCA. The pathogenicmechanisms of CRX disease have not been elucidated, and thereported Crx-/- mouse model does not reflect the human phenotype.Here, we describe a spontaneous mutant with autosomal dominantcongenital blindness named RIP (Retina with ImmaturePhotoreceptors), caused by a frameshift mutation in Crx leading tothe differentiation of retina with immature cone-like photoreceptors.Methods: Linkage analysis and exome capture sequencing were usedto identify the mutation. Fundus photography, ERG,immunohistochemistry, RNA-seq, luciferase and gel-shift assayswere performed to characterize the RIP mouse and the mutant CRXprotein. CRX and frameshift mutants were transfected in mouseretina by in vivo electroporation. Crxp::Nrl mice were used for someof the rescue experiments.Results: The RIP mutant revealed autosomal dominant pattern ofinheritance with congenital blindness and exhibited pigmentation andattenuated vasculature upon fundus examination at one-month of age.We identified a frameshift mutation in Crx resulting in the deletion ofthe Otx-like domain and an extended C-terminal region. Interestingly,several LCA-causing CRX mutations result in similar proteinmodifications. In the RIP mutant, the retinal photoreceptors hadcone-like nuclei, but no outer segments; however, unlike Crx-/- micethe photoreceptors did not degenerate. RNAseq analysis of P2 andP21 retina revealed a loss of Nrl and Nr2e3 expression and anabsence of most rod visual signaling components only at P21. Wealso showed the lack of transcriptional activity in CrxRIP was due toits inability to bind DNA. By mating RIP mutant with Crxp-Nrl micein which Nrl is expressed in all photoreceptor precursors, we partiallyrescued the phenotype due to the existence of only rods with shortouter segments. Electroporation in wild type mice of LCA-causingCRX frameshift mutations led to an arrest of photoreceptor©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Biochemistry</strong>/<strong>Molecular</strong> <strong>Biology</strong>maturation.Conclusions: Our findings show the dominant negative effect of agroup of CRX mutations preventing the establishment of rod generegulatory network and reveal the RIP mouse as a good model forLCA-causing CRX mutations.Commercial Relationships: Jerome E. Roger, None; Avinash H.Hiriyanna, None; Debbie F. Cheng, None; Norimoto Gotoh, None;Rinki Ratna Priya, None; Matthew Brooks, None; Harsha K.Rajasimha, Genome International Corporation (C), DovelTechnologies (E), George Mason University (S), Rare GenomicsInstitute (S), National Eye Institute (C); Bo Chang, None; AnandSwaroop, NoneSupport: NIH Intramural Research ProgramProgram Number: 3151Presentation Time: 11:45 AM - 12:00 PMNatriuretic peptides regulate MAP kinases via PKG to protectthe RPE from VEGF actionZsolt Ablonczy 1 , Mohammad Dahrouj 1 , Yueying Liu 1 , KumarSambamurti 2 , Craig E. Crosson 1 . 1 Ophthalmology, MedicalUniversity of South Carolina, Charleston, SC; 2 Ophthalmology,Medical University of South Carolina, Charleston, SC.Purpose: Diabetic retinopathy-associated vision loss is oftenattributed to edema within the layers of the retina. Diabetes is knownto alter the levels of natriuretic peptides (NP) expressed by the retinalpigment epithelium (RPE). However, the function of these peptidesand their contribution to diabetic retinopathy remains unclear. Wehave previously shown that NP receptor 2 (NPR-2) activation canblock the breakdown of the RPE barrier. In this project, we haveinvestigated the molecular mechanism of NP activity in the RPE.Methods: Barrier breakdown was induced in fetal human RPE cellsby 100 mg/L glycated albumin (glyc-alb) or VEGF (10 μg/L) andmeasured by transepithelial resistance (TER). NPs (ANP or CNP;nmol/L) were administered apically. Administration of the cGMPanalog, 8-Br-cGMP (100 μmol/L), or the PKG inhibitor, KT5823 (5μmol/L) was used to measure the involvement of signaling eventsdownstream of NPR-2. Enzyme-linked immunoassays determinedchanges in VEGF secretion. VEGF-R2 was inhibited by ZM323881(10 nmol/L). Map kinase activation was assessed by pretreatmentwith pathway inhibitors (U0126 for ERK1/2, SB203580 for p38,SP600125 for JNK, LY294002 for PI3K; all at 0.1-10 μM) andwestern blot analysis of ERK1/2.Results: Glycated albumin induced an apically-directed VEGFrelease paralleled with a rapid breakdown of RPE barrier function.The glyc-alb response was reversed by the administration of ANP orCNP in a concentration-dependent fashion and also by the VEGF-R2antagonist, ZM323881. However, VEGF-release was notsignificantly altered by NPs. Pretreatment with 8-Br-cGMPsubstituted NP-induced responses and pretreatment with KT5823abolished any NP-responses. VEGF-induced barrier breakdownrequired the activity of the ERK1/2 pathway but not that of the JNK,p38 and PI3K pathways. Similarly to U0126, NPs inhibited theVEGF-induced activation of ERK1/2.Conclusions: These studies provided evidence that in RPE cells, NPscan oppose the effects of advanced glycation end-products, one of themost important complicating factors in diabetes. NPR-2 activationinduced PKG, eventually targeting the ERK1/2 MAP kinasedownstream of VEGF-R2. These results are consistent with the ideathat NPs are part of an endogenous system necessary for maintainingthe barrier integrity of the RPE. Therefore, we conclude that NPsplay a critical role in protecting vision against diabetic retinopathyand retinal edema.Commercial Relationships: Zsolt Ablonczy, None; MohammadDahrouj, None; Yueying Liu, None; Kumar Sambamurti, None;Craig E. Crosson, Alimera Sciences (C), Lexicon Pharmaceuticals,Inc (R)Support: Supported by NIH/NEI EY019065 (ZA), NIH/NEIEY009741 (CEC), NIH/NIA AG022103 (KS); and an unrestrictedgrant fro RPB to the Department of Ophthalmology at MUSC.Program Number: 3152Presentation Time: 12:00 PM - 12:15 PMRestoration of vitreous structure after degradationYing-Bo Shui 1 , Benjamen Filas 1 , Qianru Zhang 1 , Shaili Sharma 3 ,Alyssa Panitch 3 , David C. Beebe 1, 2 . 1 Dept of Ophthalmology andVisual Sciences, Washington Univ Sch of Med, St Louis, MO; 2 Deptof Cell <strong>Biology</strong> and Physiology, Washington Univ Sch of Med, StLouis, MO; 3 Weldon School of Biomedical Engineering, PurdueUniversity, West Lafayette, IN.Purpose: Age-related vitreous degeneration leads to several sightthreateningdiseases, including retinal detachment, macular hole, andpre-retinal membranes. Delaying degeneration or restoring thestructure of the vitreous gel would prevent these diseases. Recently,synthetic proteoglycan mimics that bind to hyaluronic acid orcollagen have been shown to increase the compressive strength ofcartilage and protect other components of the extracellular matrixfrom proteolytic degradation, thereby replicating the functions of thecartilage proteoglycan, aggrecan. Since the vitreous is essentially“dilute cartilage,” we tested the ability of three proteoglycan mimicsto restore the physical properties and structure of trypsin-treatedbovine vitreous.Methods: A core of fresh bovine vitreous is carefully removed with atrephine and injected with PBS (sham), purified trypsin, trypsin(TRYP) plus mimics , or mimics alone. The mimics were designed tobind hyaluronan (GAH), collagen type II (WYR) or both hyaluronanand collagen type II (WYR/GAH). Samples are incubated at 4 degreeovernight and their viscoelastic properties measured using arheometer. Morphological analysis is performed by deep-etchelectron microscopy (DEEM).Results: Trypsin-treated vitreous had a significant, 50% decrease instorage modulus (stiffness) relative to untreated and PBS--shamsamples. The stiffness of vitreous samples pre-treated with trypsin iscompletely restored by addition of each of the three proteoglycanmimics. Vitreous treated with proteoglycan mimics alone also showsa tendency toward increased storage modulus but this was notstatistically significant (figure 1). In trypsin-treated vitreous DEEMshowed thinner, more discontinuous fibrils, decreased “knobby”projections and increased open space. Analysis by DEEM of trypsinandmimic-treated vitreous is in process.Conclusions: Synthetic proteoglycan mimics restore the physicalproperties of degraded vitreous and may have clinical applications forprevention of age-related retinal damage. In vivo examination of thesafety and stability the mimics in the vitreous is warranted.©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.